ACIP Presentation Slides: October 2020 Meeting
On This Page
We will add links to presentations as they are available.
October 28, 2020
Welcome & Introductions
- Welcome and Introductions [8 pages, 508]
Dr. A Cohn
Dr. J Romero
Immunization Schedules
Seasonal Influenza Vaccines
- Introduction [5 pages]
Dr. K Talbot - Efficacy of cell-derived quadrivalent influenza vaccine (Flucelvax Quadrivalent) in children & adolescents ≥2 years to <18 years old [13 pages]
Dr. G Sylvester - Influenza Disease Burden and Vaccine Impact Estimates, 2019-20 Season [21 pages]
Dr. C Reed - End-of-Season Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness against Medically Attended Influenza from three U.S. Networks [35 pages]
Dr. L Grohskopf - Updates and WG Considerations [1 page]
Dr. L Grohskopf
Orthopoxvirus Vaccine
- Introduction [10 pages]
Dr. B Bell - Orthopoxvirus work group background [25 pages]
Dr. B Petersen - JYNNEOS® (MVA-BN®) Smallpox and Monkeypox Vaccine [25 pages]
Dr. H Weidenthaler - Variola virus plaque reduction neutralization assay for the assessment of JYNNEOS(TM) vaccinee sera [10 pages]
Dr. C Hutson - Vaccinating against monkeypox in the Democratic Republic of the Congo with JYNNEOS(TM) [22 pages]
Dr. B Petersen - Next Steps [11 pages]
Dr. A Rao
Dengue Vaccines
- Introduction [12 pages, 508]
Dr. R Atmar
Pneumococcal Vaccines
- Introduction [19 pages, 508]
Dr. K Poehling
Dr. M Kobayashi
Cholera Vaccines
- Introduction [7 pages, 508]
Dr. P Sanchez
October 29, 2020
Zoster Vaccine
- Introduction [8 pages, 508]
Dr. G Lee - Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix) [13 pages, 508]
Dr. J Su - Vaccine Safety Datalink (VSD) update on post-licensure safety monitoring of RZV [11 pages, 508]
Dr. J Nelson - Risk of Guillain-Barré syndrome following herpes zoster [21 pages, 508]
Dr. T Anderson - Summary and planned risk-benefit analysis regarding use of RZV in immunocompetent adults [9 pages, 508]
Dr. T Anderson
Tick-borne Encephalitis Vaccine
- Introduction & Overview of tick-borne encephalitis (TBE) and TBE vaccine [17 pages, 508]
Dr. G Lee
Dr. S Hill - Immunogenicity and safety of Pfizer’s TBE vaccine & Next steps for TBE vaccine work group [53 pages, 508]
Dr. H Schmitt
Dr. S Hill
Rabies Vaccine
- Introduction [9 pages, 508]
Dr. S Frey - Rabies Pre-exposure Prophylaxis in the United States and Work Group Considerations [22 pages]
Dr. A Rao - Minimum acceptable rabies antibody titer [17 pages, 508]
Dr. S Moore - Pertinent fundamentals of rabies immunology [19 pages, 508]
Dr. D Briggs - Pre-exposure prophylaxis schedule: Grading of recommendations assessment, development, and evaluation (GRADE) [46 pages, 508]
Dr. A Rao - Evidence to recommendation framework (EtR) [64 pages, 508]
Dr. A Rao - Summary and next steps [15 pages, 508]
Dr. A Rao
October 30, 2020
Coronavirus Disease 2019 (COVID-19) Vaccines
- Introduction [14 pages, 508]
Dr. B Bell - Update from Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting [17 pages, 508]
Dr. D Fink - NVX-CoV2373 Vaccine Candidate [21 Pages]
Dr. F Dubovsky - Janssen’s SARS-CoV-2 Vaccine Program [15 pages]
Dr. J Sadoff - Update on vaccine implementation planning [14 pages, 508]
Dr. J Routh - Vaccinate with Confidence [11 pages, 508]
Dr. A Cohn - FDA safety surveillance systems [24 pages, 508]
Dr. S Anderson - Post-authorization safety monitoring plans [31 pages, 508]
Dr. T Shimabukuro - Modeling strategies for the initial allocation of COVID-19 vaccines [28 pages, 508]
Dr. M Biggerstaff - Updates to immunity and epidemiology to inform COVID-19 vaccine policy [57 pages, 508]
Dr. M Wallace - Ethical principles for early vaccine allocation [22 pages, 508]
Dr. M Chamberland - Work Group interpretation of data [17 pages, 508]
Dr. S Oliver - Policy questions, Evidence to Recommendation Framework, and Outcomes [11 pages, 508]
Dr. K Dooling - ACIP COVID-19 Vaccine Safety Technical Sub-Group [6 pages, 508]
Dr. M Wharton